GR890100799A - Μεθοδος παρασκευης συνθετικης ιντερλευκινης-6. - Google Patents

Μεθοδος παρασκευης συνθετικης ιντερλευκινης-6.

Info

Publication number
GR890100799A
GR890100799A GR890100799A GR890100799A GR890100799A GR 890100799 A GR890100799 A GR 890100799A GR 890100799 A GR890100799 A GR 890100799A GR 890100799 A GR890100799 A GR 890100799A GR 890100799 A GR890100799 A GR 890100799A
Authority
GR
Greece
Prior art keywords
peptide
protein
cysteine
synthetic
cells
Prior art date
Application number
GR890100799A
Other languages
English (en)
Inventor
M Dana Fowlkes
T Charles Tackney
Original Assignee
Univ North Carolina
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Imclone Systems Inc filed Critical Univ North Carolina
Publication of GR890100799A publication Critical patent/GR890100799A/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση κατευθύνεται σε ανασυνδυαστικά γονίδια και τις κωδικοποιημένες πρωτεϊνες τους οι οποίες είναι πεπτίδια με ενεργότητα IL-6. Παρόμοιες πρωτεϊνες περιλαμβάνουν το απαλλαγμένης κυστείνης συνθετικής IL-6, πεπτίδιο και το πεπτίδιο ανασυνδυασμού με κυστεϊνες. Η εφεύρεση κατευθύνεται στην συμφερτική εμπορική παραγωγή μεγάλων ποσοτήτων πεπτιδίων με IL-6 ενεργότητα με μια μορφή η οποία δεν απαιτεί τη χρήση σκληρών παραγόντων αποικοδόμησης και που δεν χρειάζονται να αναδιπλωθούν μετά την κάθαρση. Οι πρωτεϊνες της παρούσης εφεύρεσης μπορούν να χρησιμοποιηθούν προς διέγερση παραγωγής πρωτεϊνών από κύτταρα, περιλαμβανομένων κυττάρων του ανοσοποιητικού συστήματος και ηπατοκυττάρων. Οι πρωτεϊνες της παρούσης εφεύρεσης μπορεί να έχουν ενεργότητα κατά των ιών και μπορεί να προλαμβάνουν μόλυνση των κυττάρων με ιούς. Σε μια προτιμητέα πρακτική εφαρμογή το, απαλλαγμένης κυστεϊνης, συνθετικής IL-6 παρόμοιο πεπτίδιο παράγεται από μικροβιακά κύτταρα ως ένα τριυβριδικό τήγμα περιλαμβάνοντας συνθετικής απαλλαγμένης κυστεϊνης, IL-6 παρόμοιο πεπτίδιο, ένα χημικά διασπώμενο πεπτίδιο και μια πρωτεϊνη ικανή έκφρασης στον ξενιστικό οργανισμό. Μετά την κάθαρση της μεγάλης πρωτεϊνης τήξης το συνθετικής IL-6 παρόμοιο πεπτίδιο, απομακρύνεται με πέψη του μέρους κολλαγόνου της τήξης με κολλαγενάση. Η συνθετικής απαλλαγμένη κυστεϊνης IL-6 παρόμοια πρωτεϊνη καθαρίζεται με HPLC προς απόδοση μιας καθαρής πρωτεϊνης, η οποία διεγείρει την παραγωγή ανοσοσφαιρινών από τα Β-κύτταρα και διεγείρει την παραγωγή ηπατικών πρωτεϊνών. ω
GR890100799A 1988-12-01 1989-12-01 Μεθοδος παρασκευης συνθετικης ιντερλευκινης-6. GR890100799A (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27869088A 1988-12-01 1988-12-01
US44062489A 1989-11-22 1989-11-22

Publications (1)

Publication Number Publication Date
GR890100799A true GR890100799A (el) 1991-03-15

Family

ID=26959230

Family Applications (1)

Application Number Title Priority Date Filing Date
GR890100799A GR890100799A (el) 1988-12-01 1989-12-01 Μεθοδος παρασκευης συνθετικης ιντερλευκινης-6.

Country Status (8)

Country Link
EP (1) EP0446283A4 (el)
JP (1) JPH04503301A (el)
AU (1) AU639428B2 (el)
CA (1) CA2004261A1 (el)
GR (1) GR890100799A (el)
IL (1) IL92525A0 (el)
PT (1) PT92479A (el)
WO (1) WO1990006370A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
ZA924674B (en) * 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
US5338833A (en) * 1992-07-23 1994-08-16 The University Of North Carolina At Chapel Hill Carboxy terminal IL-6 muteins
WO1994003492A1 (en) * 1992-08-06 1994-02-17 The University Of Melbourne Interleukin-6 variants and uses therefor
US5338834A (en) * 1993-01-26 1994-08-16 Allelix Biopharmaceuticals Inc. Ultrapure human interleukin-6
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
JPH093099A (ja) * 1995-06-20 1997-01-07 Toyobo Co Ltd マクロファージ刺激蛋白質改変体およびその製造法
ATE386811T1 (de) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6265204B1 (en) 1997-01-17 2001-07-24 Genencor International, Inc. DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1409694A4 (en) 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6790641B2 (en) 2002-05-01 2004-09-14 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation
US20100015211A1 (en) 2004-11-01 2010-01-21 Barnett Susan W Combination Approaches For Generating Immune Responses
KR100692389B1 (ko) * 2005-04-21 2007-03-09 주식회사수산중공업 차압스위치
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP2870238A4 (en) 2012-07-05 2016-03-09 Ohio State Innovation Foundation COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
US11324816B2 (en) 2015-08-31 2022-05-10 Technovax, Inc. Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US11083786B2 (en) 2018-01-19 2021-08-10 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
CN114805537A (zh) * 2022-04-26 2022-07-29 华南农业大学 一种表达犬白介素6的重组质粒、稳定表达犬白介素6蛋白的细胞株及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62102157A (ja) * 1985-10-30 1987-05-12 Chuzo Kishimoto 抗体
EP0257406A2 (en) * 1986-08-06 1988-03-02 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
EP0326120A2 (en) * 1988-01-26 1989-08-02 Yeda Research And Development Company Limited Human IFN-beta2/IL-6, its purification and uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85204A0 (en) * 1988-01-26 1988-07-31 Yeda Res & Dev Recombinant human interferon beta2,its preparation and pharmaceutical compositions comprising it
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62102157A (ja) * 1985-10-30 1987-05-12 Chuzo Kishimoto 抗体
EP0257406A2 (en) * 1986-08-06 1988-03-02 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
EP0326120A2 (en) * 1988-01-26 1989-08-02 Yeda Research And Development Company Limited Human IFN-beta2/IL-6, its purification and uses

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY, vol. 6, no. 7, July 1988, pages 806-809, New York, NY, US; Y. ASAGOE et al.: "Human B-cell stimulatory factor-2 expressed in Escherichia coli" *
CHEMICAL ABSTRACTS, vol. 107, no. 21, 23rd November 1987, page 599, abstract no. 196394b, Columbus, Ohio, US; & JP-A-62 102 157 (T. KISHIMOTO et al.) 12-05-1987 *
CLAIMS SEARCHED: ALL *
GENE, vol. 62, 1988, pages 55-64, Amsterdam, NL; S. SCHOLTISSEK et al.: "A plasmid vector system for the expression of triprotein consisting of beta-galactosidase, a collagenase recognition site and a foreign gene product" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 81, August 1984, pages 4692-4696, Washington, US; J. GERMINO et al.: "Rapid purification of a cloned gene product by genetic fusion and site-specific proteolysis" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 83, November 1986, pages 8506-8510; B.E. SCHONER et al.: "Translation of a synthetic two-cistron mRNA in Escherichia coli" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 85, no. 24, December 1988, pages 9426-9430, Washington, DC, US; R.C. JAMBOU et al.: "High-level expression of a bioengineered, cysteine-free hepatocyte-stimulating factor (interleukin 6)-like protein" *
THE JOURNAL OF BIOCHEMISTRY, vol. 104, no. 1, July 1988, pages 30-34, Tokyo, JP; N. TONOUCHI et al.: "High-level expressiom of human BSF-2/IL-6 cDNA in Escherichia coli using a new type of expression-preparation system" *

Also Published As

Publication number Publication date
EP0446283A1 (en) 1991-09-18
CA2004261A1 (en) 1990-06-01
AU639428B2 (en) 1993-07-29
WO1990006370A1 (en) 1990-06-14
AU4801490A (en) 1990-06-26
IL92525A0 (en) 1990-08-31
EP0446283A4 (en) 1992-01-08
PT92479A (pt) 1990-06-29
JPH04503301A (ja) 1992-06-18

Similar Documents

Publication Publication Date Title
GR890100799A (el) Μεθοδος παρασκευης συνθετικης ιντερλευκινης-6.
DZ467A1 (fr) Interferon immunitaire urbain.
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DK355486D0 (da) Fusionsproteiner, deres fremstilling og anvendelse
SE9002589L (sv) Neutrofil-aktiverande peptid-2
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
DE3873397D1 (de) Bifunktionelle proteine.
AU6518386A (en) Novel vector comprising DNA sequences containing a part of polyhedral structural gene from Bombyx Mori nuclear polyhedrosis virus, and use of said vector to produce gene products by genetic engineering
ATE159952T1 (de) Peptid-determinante mit einfluss auf die immunität
DK0652903T3 (da) Nyt humant rekombinant gammainterferon
DK288789A (da) Peptider og syreadditionssalte deraf, deres fremstilling og anvendelse
ES2146193T1 (es) Proteinas del virus del arrugado de las hojas de la vid (tipo 2) y sus usos.
DE60126602D1 (de) Neue collectine
KR880701073A (ko) 제조합 dna 기법에 의해 생성된 민악티빈
CA2006587A1 (en) Membrane proteins and peptides of haemophilus influenzae type b
IT8919634A0 (it) Procedimento per la preparazione su scala industriale di interferon di leucocita umano ad alta purezza e terapeuticamente utile.